CONTI ELISA
- U08, Piano: 2, Stanza: 2056
Pubblicazioni
Pozzi, F., Conti, E., Remoli, G., Dell'Orto, N., Andreoni, S., Da Re, F., et al. (2025). Core blood biomarkers of Alzheimer's disease: A single-center real-world performance study. JPAD, 12(2) [10.1016/j.tjpad.2024.100027]. Dettaglio
de Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I., et al. (2023). Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (Nature Communications, (2021), 12, 1, (3417), 10.1038/s41467-021-22491-8) [Altro] [10.1038/s41467-023-36192-x]. Dettaglio
Turri, M., Conti, E., Pavanello, C., Gastoldi, F., Palumbo, M., Bernini, F., et al. (2023). Plasma and cerebrospinal fluid cholesterol esterification is hampered in Alzheimer's disease. ALZHEIMER'S RESEARCH & THERAPY, 15(1 (December 2023)) [10.1186/s13195-023-01241-6]. Dettaglio
Pozzi, F., Cerina, V., Licciardo, D., Guo, W., Brambilla, A., Cosentino, G., et al. (2023). Clinical applicability of pCASL as a substitute for FDG-PET in the etiological diagnosis of MCI and SCD: CAPE study protocol. Intervento presentato a: Neuromi 2023, Milano, Italia. Dettaglio
Saresella, M., Zoia, C., La Rosa, F., Bazzini, C., Sala, G., Grassenis, E., et al. (2023). Glibenclamide-Loaded Engineered Nanovectors (GNVs) Modulate Autophagy and NLRP3-Inflammasome Activation. PHARMACEUTICALS, 16(12) [10.3390/ph16121725]. Dettaglio